Apheresis for chimeric antigen receptor T‐cell production in adult lymphoma patients

To date, in‐depth analysis of leukapheresis products as starting material for CAR T‐cell manufacturing, specifically Tisagenlecleucel production, are scarce. In this study, we report on lymphapheresis data for production of Tisagenlecleucel for elderly and pretreated lymphoma patients.

[1]  Gregory M. Chen,et al.  Decade-long leukaemia remissions with persistence of CD4+ CAR T cells , 2022, Nature.

[2]  He Huang,et al.  Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering , 2022, Frontiers in Oncology.

[3]  H. Abken.  Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors , 2021, Human gene therapy.

[4]  K. Akashi,et al.  Optimization of lymphapheresis for manufacturing autologous CAR-T cells , 2021, International Journal of Hematology.

[5]  E. Seifried,et al.  Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients , 2020, Journal of clinical apheresis.

[6]  P. Dreger,et al.  Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL , 2020, Cells.

[7]  M. von Bergwelt-Baildon,et al.  Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy , 2019, Transfusion Medicine and Hemotherapy.

[8]  G. Salles,et al.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.

[9]  U. Uslu,et al.  CAR‐T cell therapy in melanoma: A future success story? , 2018, Experimental dermatology.

[10]  Carl H. June,et al.  Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology , 2018, Front. Immunol..

[11]  Michel Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[12]  Avery D Posey,et al.  Driving cars to the clinic for solid tumors , 2018, Gene Therapy.

[13]  Francesco Ceppi,et al.  Lymphocyte apheresis for chimeric antigen receptor T‐cell manufacturing in children and young adults with leukemia and neuroblastoma , 2018, Transfusion.

[14]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[15]  J. Whitlock,et al.  Optimizing autologous nonmobilized mononuclear cell collections for cellular therapy in pediatric patients with high‐risk leukemia , 2017, Transfusion.

[16]  D. Stroncek,et al.  Autologous lymphapheresis for the production of chimeric antigen receptor T cells , 2017, Transfusion.

[17]  M. Jensen,et al.  Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility , 2016, Clinical Cancer Research.

[18]  A. Fesnak,et al.  CAR-T Cell Therapies From the Transfusion Medicine Perspective. , 2016, Transfusion medicine reviews.

[19]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[20]  A. Ziman,et al.  Moderate and severe adverse events associated with apheresis donations: incidences and risk factors , 2010, Transfusion.